Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Syntrophic interactions driving anaerobic methane oxidation in deep-sea cold seeps revealed by DNA-SIP.

iScience·2026

Same author

Safety and Efficacy of Plerixafor in Poor Mobilizers With Lymphoma: A Multicenter, Prospective, Single-Arm Study.

American journal of hematology·2026

Same author

Pre-Transplant MRD Negativity and Age Under 40 Predict Superior Long-Term Survival in Relapsed/Refractory B-ALL After CAR-T Therapy Bridging to Haploidentical HSCT: A Multicenter Retrospective Study With 6-Year Follow-Up.

American journal of hematology·2026

Same author

Hemophagocytic Lymphohistiocytosis After CAR T-Cell Therapy: A Systematic Review and Meta-Analysis.

American journal of hematology·2026

Same author

Correction: A novel immune model predicts the prognosis of mantle cell lymphoma.

Frontiers in medicine·2026

Same author

Phase I/II Trial of the FLT3 Kinase Inhibitor XY0206 in Patients With Relapsed/Refractory Acute Myeloid Leukemia.

European journal of haematology·2026

Same journal

The Distribution of Kell Blood Group Antigens and Phenotypes (K and K) Among Saudi Blood Donors of King Abdulaziz Medical City - Western Region: A Cross-Sectional Study.

Journal of blood medicine·2026

Same journal

A Delphi Consensus by Hematologists on the Burden of Treatment on Patients with Severe Hemophilia in Mexico.

Journal of blood medicine·2026

Same journal

A Clinical Investigation of Hypoxic Red Blood Cell Administration in Patients with Transfusion-Dependent Hematological Malignancies and Burns.

Journal of blood medicine·2026

Same journal

ATG Plus Post-Transplantation Cyclophosphamide Improves EBV-DNA Clearance and GVHD in Patients of Adult Chronic Active Epstein-Barr Virus Disease Undergoing Allogeneic HSCT.

Journal of blood medicine·2026

Same journal

Care Patterns, Outcomes, and Costs in Peripheral T-Cell Lymphoma Patients with First-Line Treatment in Routine Clinical Practice in Europe.

Journal of blood medicine·2026

Same journal

Malignancy-Associated Hemophagocytic Lymphohistiocytosis: An Experience of 15 Years in Polish Pediatric Hematology Centers.

Journal of blood medicine·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jun 12, 2026

VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma

VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma

Published on: December 28, 2015

Specific Mutation Predict Relapse/Refractory Diffuse Large B-Cell Lymphoma.

Jing Wang¹, Lei Tian², Weilong Zhang¹

¹Department of Hematology, Lymphoma Research Center, Peking University Third Hospital, Beijing, 100191, People's Republic of China.

Journal of Blood Medicine

|September 16, 2024

Summary

This summary is machine-generated.

Gene mutations like CD58 may predict relapse/refractory diffuse large B-cell lymphoma (DLBCL). TP53, MEF2B, and CD58 mutations were more common in patients who progressed. CD58 mutations were exclusive to the relapse/refractory group.

Keywords:

diffuse large B-cell lymphoma mutation profile relapse/refractory disease targeted sequencing

More Related Videos

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

Enhancing Tumor Content through Tumor Macrodissection

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

Related Experiment Videos

Last Updated: Jun 12, 2026

VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma

VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma

Published on: December 28, 2015

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

Enhancing Tumor Content through Tumor Macrodissection

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

Area of Science:

Hematology
Oncology
Genetics

Background:

Rituximab therapy improves survival in diffuse large B-cell lymphoma (DLBCL).
A substantial proportion of DLBCL patients still develop relapse/refractory disease (rrDLBCL).

Purpose of the Study:

To investigate gene mutations as predictors of progression to rrDLBCL.
To compare mutation profiles between DLBCL at diagnosis and rrDLBCL cases.

Main Methods:

Targeted sequencing of 55 genes was performed.
Mutation profiles were analyzed in diagnostic biopsies and rrDLBCL samples.

Main Results:

Elevated mutation frequencies of TP53, MEF2B, and CD58 were observed in patients who progressed to rrDLBCL.
CD58 mutations were exclusively found in the rrDLBCL group.
CARD11 mutations were more frequent in non-responders to immunochemotherapy, while EBF1 mutations were specific to rrDLBCL.

Conclusions:

Genetic mutations contribute to rrDLBCL progression.
CD58 mutations may serve as a predictive marker for relapse/refractory outcomes in DLBCL.